Migraine Patients Treated With Erenumab and the Risk of Hypertension: A Registry-Based Real-World Study
Abstract
BACKGROUND: Recent post-marketing studies have indicated a possible association between anti-CGRP receptor monoclonal antibodies (anti-CGRP-mAbs) used for migraine prophylaxis and an increased risk of hypertension (HT).
METHODS: We performed a retrospective real-world exploratory study, including individuals with a confirmed diagnosis of migraine who were treated with erenumab, an anti-CGRP receptor (r)-mAb, for at least 12 months. Inclusion was limited to individuals with complete clinical records and regular follow-up, with at least one visit every 3 months and data available to assess treatment outcomes. Patients were excluded if they had previously received anti-CGRP mAbs or gepants for migraine prevention before starting the current therapy, were on any concomitant baseline migraine preventive treatment, or did not complete the 12-month follow-up visits.
RESULTS: One hundred twenty-five participants were eligible and included in the analysis. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were compared between baseline and follow-up visits, conducted every 3 months for up to 24 months while the patient was on treatment. Individuals treated with erenumab initially received 70 mg, administered subcutaneously every 4 weeks. Throughout the 12-month treatment period, blood pressure (BP) measurements remained stable and within normal physiological ranges, indicating no significant hypertensive effect. Analysis across multiple visits showed that SBP ranged…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 54 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.